Allarity Therapeutics Inc (ALLR)
$1.57
Live
Performance
- $1.53$1.78$1.57
2.55%
Downside
Day's Volatility :14.04%
Upside
11.8%
- $1.36$666.00$1.57
13.38%
Downside
52 Weeks Volatility :99.8%
Upside
99.76%
Returns
| Period | Allarity Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -64.84% | 0.0% |
6 Months | -95.94% | 0.0% |
1 Year | -99.55% | 0.0% |
3 Years | -100.0% | -23.0% |
Highlights
Market Capitalization | 2.4M |
Book Value | $16.98 |
Earnings Per Share (EPS) | -10.98 |
Wall Street Target Price | 5.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -47.72% |
Return On Equity TTM | -121.82% |
Revenue TTM | -7.1M |
Revenue Per Share TTM | -0.02 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -36.3M |
EBITDA | -16.9M |
Diluted Eps TTM | -10.98 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -78.12 |
EPS Estimate Next Year | -46.92 |
EPS Estimate Current Quarter | -0.29 |
EPS Estimate Next Quarter | -0.28 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 218.47%
Technicals Summary
Sell
Neutral
Buy
Allarity Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Allarity Therapeutics Inc | -22.77% | -95.94% | -99.55% | -100.0% | -100.0% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Allarity Therapeutics Inc | 0.0 | NA | NA | -78.12 | -1.22 | -0.48 | NA | 16.98 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Allarity Therapeutics Inc | Sell | $2.4M | -100.0% | 0.0 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Allarity Therapeutics Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 182.5%
Institutional Holdings
Virtu Financial LLC
0.63%Geode Capital Management, LLC
0.24%UBS Group AG
0.10%Jump Financial, LLC
0.09%HRT FINANCIAL LLC
0.08%JANE STREET GROUP, LLC
0.04%
Company Information
oncology venture is a drug development company formed in 2012 dedicated to unlock the potential of new oncology products, and rescue failed drugs. our method improves the efficacy of the drugs, increase the response rate in cancer patients, reduce timelines and improve success rates in oncology drug development.
Organization | Allarity Therapeutics Inc |
Employees | 5 |
CEO | Mr. Thomas H. Jensen |
Industry | Miscellaneous |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.57
-9.25%
Invesco Bulletshares 2025 Hi
$1.57
-9.25%
Schwab International Dividend Equity Etf
$1.57
-9.25%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.57
-9.25%
Lightpath Technologies Inc
$1.57
-9.25%
Vaneck Vectors Global Alternative Energy Etf
$1.57
-9.25%
First Trust Flexible Municipal High Income Etf
$1.57
-9.25%
Drx Dly Reg Bank Bull 3x
$1.57
-9.25%
Graniteshares 2x Long Pltr Daily Etf
$1.57
-9.25%